MedPage Today) -- A pembrolizumab (Keytruda) combination led to an overall survival (OS) boost in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer, according to results from the KEYNOTE-A18 trial...
GET PAID FOR SHOPPING AT ALL YOUR FAVORITE STORES!
Sound too good to be true? Here’s the deal: Stores pay us a commission for sending you their way.
We share that with you as Cash Back. Everyone wins! SIGN UP FOR FREE!
.png)
COOL ROOM ENTERTAINMENT 10530 Campus Way South #1174 Largo, MD 20774
(916) 619-1308
teosmoot@gmail.com
Copyright © 2024 Cool Room Entertainment. All Rights Reserved
